Dentsply Sirona Reports Third Quarter 2026 Results
Dentsply Sirona reported Q3 2026 net sales of $836 million, down 7.6% year-over-year, with a GAAP diluted loss per share of $0.01 and adjusted EPS of $0.29, down 29.4% from $0.42. Positives included record quarterly sales at Wellspect Healthcare (up 10.1%), GAAP gross margin expansion to 52.9% from 48.8%, and completion of the U.S. Surity portfolio launch. However, results included a $39 million one-time inventory-profit-estimate benefit that boosted gross profit and adjusted earnings by roughly $30 million.
Key figures
- Revenue
- 836000000
- Guidance
- FY2026 net sales approximately $3.5 billion; adjusted EPS $1.20 to $1.30, excluding a $0.17 one-time benefit from tariff refunds
- Revenue Yoy
- -7.6%
- Q3 buyback
- 13000000
- Ytd buyback
- 25000000
- Adjusted eps
- 0.29
- Free cash flow
- 0
- Adjusted ebitda
- 146000000
- Adjusted eps yoy
- -29.4%
- Gaap gross margin
- 52.9%
- Operating cash flow
- 32000000
- Cash and equivalents
- 195000000
- Adjusted gross margin
- 54.5%
- Adjusted ebitda margin
- 17.3%
- Wellspect sales growth
- 10.1%
- Inventory profit estimate benefit
- 39000000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.